Drug Profile
RP L101
Alternative Names: Fanconi's anaemia gene therapy - Rocket Pharmaceuticals; LP L01; RP-L101Latest Information Update: 24 May 2019
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Fred Hutchinson Cancer Research Center; National Cancer Institute (USA); National Heart, Lung and Blood Institute; Rocket Pharmaceuticals
- Class Antianaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Fanconi's anaemia